Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up results from JCOG1704.
Gastric CancerJun 10, 2026 (epub)
Yukinori Kurokawa, Yuichiro Doki, Junki Mizusawa et al.
✦ AI-curated · Sources linked
In 30 seconds
The JCOG1704 phase II trial evaluated preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 in patients with marginally resectable gastric cancer and extensive lymph node metastasis. Among 46 eligible patients, the 3-year overall survival was 86.7%, indicating promising long-term outcomes following this treatment regimen.
Key findings
- The 3-year overall survival was 86.7% (95% CI 72.7-93.8%) among 46 eligible patients.
- Progression-free survival at 3 years was 75.6% (95% CI 60.2-85.6%).
- Among 42 patients who underwent R0 resection, the 3-year relapse-free survival was 78.6% (95% CI 62.9-88.2%).
- Subgroup analysis showed 3-year OS of 93.8% in patients with para-aortic node metastasis only.
Why it matters
These findings suggest that preoperative DOS may improve survival outcomes in patients with marginally resectable gastric cancer, potentially influencing treatment protocols and patient management strategies in this challenging population.